KRAS and cancer: Nearly 95% of PDAC tumors harbor KRAS mutations and 70% of PDAC tumors have KRAS and TP53 mutations.[1] Different cancer subtypes with different secretory states and the presence of non‐tumor cells such as fibroblasts and immune cells constitute intratumor heterogeneity of PDAC.[14, 19] Here we compared mouse PDAC cell lines harboring KrasG12D and Trp53R172H mutations (KPC), KPC1245, 8060, and 8069, in the secretion of PDAC prognostic cytokines.